Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles virus vaccine live attenuated
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Measles virus vaccine live attenuated is a biologic immunizing agent used to prevent infection by the measles (rubeola) virus. It consists of a weakened (attenuated) form of the measles virus, typically derived from the Enders' Edmonston strain and propagated in chick embryo cell culture. The vaccine stimulates active immunity by inducing the body to produce protective antibodies against the measles virus, thereby preventing disease upon exposure. While monovalent formulations were previously available (e.g., Attenuvax), most current vaccines are combination products such as M-M-R II or PRIORIX, which also protect against mumps and rubella. The primary indication is for active immunization in children 12 months of age and older, but it may be used earlier in special circumstances. The main route of administration is subcutaneous or intramuscular injection[3][5][7].
- Brand names
- AttenuvaxM-M-R IIPRIORIXProQuad
- Other names
- measles vaccine live attenuatedrubeola vaccine live attenuated
02
Targets
CD46 (CD46 Molecule)PVRL4 (Nectin cell adhesion molecule 4)SLAMF1 (SLAM family member 1)STAT1 (Signal transducer and activator of transcription protein 1)STAT2
Beyond the preview
Go deeper on measles virus vaccine live attenuated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles virus vaccine live attenuated.